Vanguard Group
NRIX icon

Vanguard Group’s Nurix Therapeutics NRIX Stock Holding History

Vanguard Group’s Portfolio NRIX Stock Details NRIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		$113M Buy
5,949,512
+1,460,736
+33% +$21M ﹤0.01% 1826
2025
Q3 		$41.5M Buy
4,488,776
+23,269
+0.5% +$242K ﹤0.01% 2252
2025
Q2 		$50.9M Buy
4,465,507
+50,385
+1% +$544K ﹤0.01% 2108
2025
Q1 		$52.5M Buy
4,415,122
+69,856
+2% +$1.17M ﹤0.01% 2081
2024
Q4 		$81.9M Buy
4,345,266
+333,452
+8% +$7.64M ﹤0.01% 1949
2024
Q3 		$90.1M Buy
4,011,814
+386,800
+11% +$8.76M ﹤0.01% 1921
2024
Q2 		$75.7M Buy
3,625,014
+1,040,714
+40% +$16.2M ﹤0.01% 1969
2024
Q1 		$38M Sell
2,584,300
-13,797
-0.5% -$148K ﹤0.01% 2284
2023
Q4 		$26.8M Sell
2,598,097
-116,748
-4% -$800K ﹤0.01% 2463
2023
Q3 		$21.3M Buy
2,714,845
+22,804
+0.8% +$208K ﹤0.01% 2522
2023
Q2 		$26.9M Buy
2,692,041
+68,586
+3% +$699K ﹤0.01% 2464
2023
Q1 		$23.3M Buy
2,623,455
+420,850
+19% +$4.39M ﹤0.01% 2530
2022
Q4 		$24.2M Buy
2,202,605
+41,739
+2% +$503K ﹤0.01% 2532
2022
Q3 		$28.2M Buy
2,160,866
+49,370
+2% +$781K ﹤0.01% 2476
2022
Q2 		$26.8M Buy
2,111,496
+83,433
+4% +$946K ﹤0.01% 2502
2022
Q1 		$28.4M Buy
2,028,063
+37,499
+2% +$666K ﹤0.01% 2587
2021
Q4 		$57.6M Buy
1,990,564
+12,613
+0.6% +$382K ﹤0.01% 2267
2021
Q3 		$59.3M Buy
1,977,951
+511,814
+35% +$15.8M ﹤0.01% 2270
2021
Q2 		$38.9M Buy
1,466,137
+303,153
+26% +$8.9M ﹤0.01% 2501
2021
Q1 		$36.2M Buy
1,162,984
+544,999
+88% +$20.6M ﹤0.01% 2482
2020
Q4 		$20.3M Buy
617,985
+81,865
+15% +$2.71M ﹤0.01% 2624
2020
Q3 		$18.7M Buy
+536,120
New +$13.5M ﹤0.01% 2489

Other funds holding NRIX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
GA
General Atlantic New York $2.15B AUM 35.02% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Vanguard Group's NRIX Position: Q4 2025 in Review

Vanguard Group increased its Nurix Therapeutics (NRIX) stake by 33% in Q4 2025, buying an estimated $21M and bringing the position to 5,949,512 shares worth $113M. The position accounts for ﹤0.01% of the portfolio, ranked #1826.

Vanguard Group first reported a position in NRIX in Q3 2020 and has held it in 22 quarters since. 182 funds tracked by Wall St. Rank hold NRIX as of Q4 2025.

  • Vanguard Group held 5,949,512 shares of Nurix Therapeutics worth $113M as of Q4 2025.
  • Vanguard Group bought 1,460,736 Nurix Therapeutics shares in Q4 2025, an estimated $21M.
  • Nurix Therapeutics made up ﹤0.01% of Vanguard Group's portfolio in Q4 2025, its #1826 holding.
  • Vanguard Group first reported a position in Nurix Therapeutics in Q3 2020 and has held it in 22 quarters since.
  • 182 funds tracked by Wall St. Rank held Nurix Therapeutics as of Q4 2025.

Based on Vanguard Group's 13F filing for Q4 2025, filed 29 Jan 2026.